Skip to main content

Advertisement

SpringerLink
Log in

Oncolytic intralesional therapy for metastatic melanoma

  • Review
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

This article has been updated

Abstract

In-transit metastasis (ITM) develop in approximately 1 in 10 patients with melanoma and the disease course can vary widely. Surgical resection is the gold-standard treatment; however, ITM are often surgically unresectable due to size, distribution, and/or anatomic involvement. Oncolytic viral therapies are one category of non-surgical treatment options available for ITM. They induce tumor cell lysis and systemic anti-tumor activity through selective infection of tumor cells by naturally occurring or genetically modified factors. While there are numerous oncolytic viral therapies in various stages of development for the treatment of ITM, this discussion focuses on the mechanism and available literature for the two most established herpes virus-based therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data Availability

This is a review article of previously published information.

Change history

  • 18 August 2023

    The Given Name and Family Name of the author Roger Olofsson Bagge has been updated.

References

  1. Borgstein PJ, Meijer S, van Diest PJ (1999) Are locoregional cutaneous metastases in melanoma predictable? Ann Surg Oncol 6(3):315–321

    Article  CAS  PubMed  Google Scholar 

  2. Pawlik TM, Ross MI, Thompson JF, Eggermont AM, Gershenwald JE (2005) The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol 23(21):4588–4590

    Article  PubMed  Google Scholar 

  3. Gershenwald JE, Scolyer RA, Hess KR et al (2017) Melanoma staging: evidence-based changes in the american Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(6):472–492

    Article  PubMed  PubMed Central  Google Scholar 

  4. Wesslau H, Carlander A, Ny L, Wärnberg F, Olofsson Bagge R, Lindqvist Bagge AS (2022) Tumor Burden and Health-Related Quality of Life in patients with Melanoma In-Transit metastases. Cancers (Basel). 15(1)

  5. Morton DL, Eilber FR, Holmes EC et al (1974) BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 180(4):635

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Bast RC Jr, Zbar B, Borsos T, Rapp HJ (1974) BCG and cancer. N Engl J Med 290(26):1458–1469

    Article  PubMed  Google Scholar 

  7. Robinson JC (1977) Risks of BCG intralesional therapy: an experience with melanoma. J Surg Oncol 9(6):587–593

    Article  CAS  PubMed  Google Scholar 

  8. Agarwala SS, Neuberg D, Park Y, Kirkwood JM (2004) Mature results of a phase III randomized trial of bacillus Calmette–Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of american Joint Committee on Cancer Stage I–III melanoma (E1673) a trial of the Eastern Cooperative Oncology Group. Cancer: Interdisciplinary International Journal of the American Cancer Society 100(8):1692–1698

    Article  CAS  Google Scholar 

  9. Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372(26):2521–2532

    Article  CAS  PubMed  Google Scholar 

  12. Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–330

    Article  CAS  PubMed  Google Scholar 

  13. Weber J, Mandala M, Del Vecchio M et al (2017) Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 377(19):1824–1835

    Article  CAS  PubMed  Google Scholar 

  14. Olofsson Bagge R, Ny L, Ascierto PA et al (2021) The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. Melanoma Res 31(2):181–185

    Article  CAS  PubMed  Google Scholar 

  15. Andtbacka RH, Kaufman HL, Collichio F et al (2015) Talimogene Laherparepvec improves durable response rate in patients with Advanced Melanoma. J Clin Oncol 33(25):2780–2788

    Article  CAS  PubMed  Google Scholar 

  16. Milhem MM, Vanderwalde AM, Bowles TL et al (2022) Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE). J Clin Oncol 40(16suppl):9553–9553

    Article  Google Scholar 

  17. Miura JT, Kroon HM, Beasley GM et al (2019) Long-term oncologic outcomes after isolated limb infusion for Locoregionally metastatic melanoma: an International Multicenter Analysis. Ann Surg Oncol 26(8):2486–2494

    Article  PubMed  PubMed Central  Google Scholar 

  18. Kaufman HL, Kohlhapp FJ, Zloza A (2015) Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14(9):642–662

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Andtbacka RH, Ross M, Puzanov I et al (2016) Patterns of clinical response with Talimogene Laherparepvec (T-VEC) in patients with Melanoma treated in the OPTiM Phase III Clinical Trial. Ann Surg Oncol 23(13):4169–4177

    Article  PubMed  PubMed Central  Google Scholar 

  20. Perez MC, Miura JT, Naqvi SMH et al (2018) Talimogene Laherparepvec (TVEC) for the treatment of Advanced Melanoma: a Single-Institution experience. Ann Surg Oncol 25(13):3960–3965

    Article  PubMed  PubMed Central  Google Scholar 

  21. Louie RJ, Perez MC, Jajja MR et al (2019) Real-world outcomes of Talimogene Laherparepvec Therapy: a multi-institutional experience. J Am Coll Surg 228(4):644–649

    Article  PubMed  Google Scholar 

  22. Carr MJ, Sun J, DePalo D et al (2021) Talimogene Laherparepvec (TVEC) for the treatment of Advanced Locoregional Melanoma after failure of Immunotherapy: a multi-institutional experience. Ann Surg Oncol.

  23. Chesney JA, Ribas A, Long GV et al (2022) Randomized, Double-Blind, Placebo-Controlled, global phase III trial of Talimogene Laherparepvec Combined with Pembrolizumab for Advanced Melanoma. J Clin Oncol. Jco2200343

  24. Chesney J, Puzanov I, Collichio F et al (2019) Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma. Br J Cancer 121(5):417–420

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Chesney J, Puzanov I, Collichio F et al (2018) Randomized, open-label phase II study evaluating the efficacy and safety of Talimogene Laherparepvec in Combination with Ipilimumab Versus Ipilimumab alone in patients with Advanced, Unresectable Melanoma. J Clin Oncol 36(17):1658–1667

    Article  CAS  PubMed  Google Scholar 

  26. Dummer R, Gyorki DE, Hyngstrom J et al (2021) Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. Nat Med 27(10):1789–1796

    Article  CAS  PubMed  Google Scholar 

  27. Replimune announces positive initial data (2022) From the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial & an RP2/3 program update [press release], vol 7. Replimune

Download references

Funding

No external funding supported this work.

Author information

Author notes

  1. Danielle K DePalo and Matthew C. Perez are shared co-first authors.

Authors and Affiliations

  1. Department of Cutaneous Oncology, Moffitt Cancer Center, 10920 McKinley Drive Room 4123, Tampa, FL, USA

    Danielle K DePalo, Matthew C. Perez & Jonathan S. Zager

  2. Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden

    Anne Huibers & Roger Olofsson Bagge

  3. Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden

    Anne Huibers & Roger Olofsson Bagge

  4. Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA

    Jonathan S. Zager

Authors
  1. Danielle K DePalo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew C. Perez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne Huibers
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roger Olofsson Bagge
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jonathan S. Zager
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

D.K.D., M.C.P., and J.S.Z. made substantial contributions to the conception or design of the work and the acquisition, analysis, and interpretation of data for the work. D.K.D., M.C.P., and J.S.Z contributed to the drafting of the work and D.K.D, M.C.P., A.H., R.O.B., and J.S.Z. contributed to the critical revision for important intellectual content. D.K.D, M.C.P., A.H., R.O.B., and J.S.Z. provided final approval of the version to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Corresponding author

Correspondence to Jonathan S. Zager.

Ethics declarations

Competing interests

D.K.D., M.C.P., and A.H. declare no conflicts of interest. R.O.B. has received institutional research grants from Bristol-Myers Squibb (BMS), Endomagnetics Ltd (Endomag) and SkyLineDx, speaker honorarium from Roche, Pfizer and Pierre-Fabre, and has served on advisory boards for Amgen, BD/BARD, Bristol-Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Novartis, Roche and Sanofi Genzyme, and is a shareholder in SATMEG Ventures AB. J.S.Z. has advisory board relationships and has received fees from with Merck, Novartis, Philogen, Castle Biosciences, Pfizer, and Sun Pharma. He also received research funding from Amgen, Delcath Systems, Philogen, and Provectus. He serves on the medical advisory board for Delcath Systems.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Presented at the 9th International Congress on Cancer Metastasis through the Lymphovascular System, May 4–6, 2023, in San Francisco, CA. To be published in a Special Issue of Clinical and Experimental Metastasis: Molecular Mechanisms of Cancer Metastasis.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

DePalo, D.K., Perez, M.C., Huibers, A. et al. Oncolytic intralesional therapy for metastatic melanoma. Clin Exp Metastasis (2023). https://doi.org/10.1007/s10585-023-10228-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10585-023-10228-4

Keywords

Search

Navigation